Skip to content
BY 4.0 license Open Access Published by De Gruyter January 20, 2017

Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis

  • Fereshteh Alsahebfosoul , Ilnaz Rahimmanesh , Mansour Shajarian EMAIL logo , Masoud Etemadifar EMAIL logo , Nahid Sedaghat , Zahra Hejazi and Shamsi Naderi
From the journal Biomolecular Concepts

Abstract

Cytokines are implicated in the immunopathogenesis of multiple sclerosis (MS). Interleukin (IL)-33, one of the recently discovered members of the IL-1 superfamily, is a dual functional cytokine involved in various autoimmune disorders. In a case-control study, venous blood was collected from healthy subjects categorized as control group (n=44) and MS patients (n=44). All recruited patients were clinically diagnosed with relapsing-remitting MS (RRMS), including patients without treatment (new identified cases, n=16) and those treated with interferon beta (IFN-β) (n=28). The plasma levels of IL-33 in subjects were measured with ELISA. Significantly elevated IL-33 plasma levels were observed in RRMS patients (p=0.005). Furthermore, IFN-β-treated MS patients had lower levels of IL-33 compared to the untreated patients (p<0.001). Increased IL-33 plasma levels in the patient group might be associated with development of MS. These results could contribute to our better understanding about the role of IL-33 in the immunopathogenesis of MS.

Introduction

Multiple sclerosis (MS) is a neuroinflammatory disease of the central nervous system (CNS), identified by lesions in the brain’s white matter and progressive disability in neuronal function (1). The age of onset of MS has been reported to be varying between 20 and 40 years (2). Some studies report that MS might slightly develop in either children or people above 60 years (3), (4), (5). Researchers have conflicting ideas on whether MS is a pathological disease, as MS presents with a variety of signs and symptoms (6), (7). Clinical investigations have demonstrated the role of immune cells in the progression of neural lesions during the acute early phase of MS, where relapses occur in the white matter of neurons and inside tracts in the gray matter, mainly because of inflammatory reactions. The main pathologic sign of MS is plaque in the demyelinated neurons, with immunocytological activity of resident immune cells during the course of the disease (8), (9), (10), (11). Numerous clinical studies have shown that MS lesions are initiated by leukocyte cell types, including lymphocytes, macrophages and dendritic cells through various immunological mechanisms such as cytokine production (10), (12).

Cytokines have various functions in health and diseases, especially in MS (13), (14), (15), (16). One of the most important cytokines that directly contributes to the immunopathogenesis of MS is IL-33 (17), a recently discovered cytokine, taking part in various inflammatory and autoimmune diseases like psoriasis, lupus erythematous, ulcerative colitis and MS (17), (18), (19), (20). ST2L, a receptor of IL-33, is expressed on the surface of various subsets of leukocytes and conducts signals to activate the MAPK and nuclear factor κB (NF-κB) pathways by TNF receptor-associated factor 6 (TRAF6) (21), (22). The IL-33/ST2 pathway is pivotal to inflammatory responses and autoimmune disorders (23). It has been reported that ST2L is principal for the inflammatory activity of IL-33 because of expression on several immune cells like endothelial cells, mast cells, macrophages, basophiles and dendritic cells (18), (19), (24), (25), (26), (27), (28).

Isfahan is one of the highest MS reported rate areas in Oceania and Asia (5), (29), (30), (31), (32), (33). Regarding the possible role of IL-33 in MS progression, we assessed IL-33 plasma levels in MS patients in comparison with healthy subjects.

Materials and methods

Patient selection

Venous blood samples (3–5 ml) were collected and plasma was isolated from 44 relapsing-remitting multiple sclerosis (RRMS) patients and 44 gender, race and age-matched healthy subjects with no previous neurological problem history. All patients were clinically diagnosed with RRMS according to the McDonald criteria (7) and no one used steroids or other medication to alleviate clinical symptom. The patient group was divided into two subsets, interferon beta (IFN-β)-treated and newly diagnosed MS patients with no treatment initiation. None of our patients underwent clinical worsening in the preceding weeks. The study was approved by the Ethical Committee on Human Research in Isfahan University of Medical Sciences and informed consent was obtained from patients participating in this study. Details of data gathering and sampling have already been published (34), (35).

Cytokine ELISA

The plasma levels of IL-33 were measured by an enzyme-linked immunosorbent assay (ELISA) kit (BOSTER Immunoleader, CA, USA) according to the manufacturer’s instructions.

Statistical analysis

In order to check the normal distribution of plasma levels, a Kolmogorov-Smirnov Z-test was performed. Assessment of association between mean plasma levels and various subjects’ factors was carried out by ANOVA and independent t-tests in the control subjects and Mann-Whitney and Kruskal-Wallis tests in the patient group (Table 2). The comparison of IL-33 plasma concentrations between the case and healthy groups was evaluated by the Mann-Whitney test. Data was demonstrated as mean±SD for age and sex (Table 1)and mean±SEM for comparison of IL-33 plasma level with various subjects’ characteristic factors (Table 2). p-Values of less than 0.05 were considered as statistically significant and all p-values were two-tailed. Statistical analysis was executed using SPSS version 16.

Table 1:

Comparison of mean IL-33 plasma levels in different factors within each group.

Groups Factors Mean±SEMa p-Valueb
Case Sex
 Male (n =6) 106.91±64.08 0.688
 Female (n=38) 195.28±131.18
Age (years)
 15–25 (n=4) 33.39±4.22 0.417
 26–35 (n=17) 66.20±24.51
 36–45 (n=13) 97.29±63.69
 Greater than 45 (n=10) 57.07±23.60
History of viral disease
 Yes (n=10) 69.03±20.10 0.261
 No (n=34) 75.79±26.87
Family history of MS
 Yes (n=11) 43.91±14.69 0.630
 No (n=33) 84.37±27.68
Control Sex
 Male (n=6) 22.50±6.32 0.808
 Female (n=38) 24.30±3.38
Age (years)
 15–25 (n=1) 40.49±0 0.816
 26–35 (n=12) 21.84±2.34
 36–45 (n=29) 26.28±10.69
 Greater than 45 (n=2) 19.73±4.95

aMean±SEM (pg/ml).

bp-Values are two-tailed.

Table 2:

Mean IL-33 plasma levels in MS and control groups.

Control (n=44) Case (n=44) p-Valuea
Total 24.05±3.02b 74.25±21.15 0.005
Treated (n=28) 55.87±24.26 0.031c
Untreated (n=16) 84.76±9.35 0.018c

ap-Values are two-tailed.

bData are shown as mean±SEM (pg/ml).

cCompared with control group.

Results

Main characteristics of patients and healthy controls

Information on age and gender of patients and healthy controls showed that both groups were matched for gender and age (p>0.05).

Characteristic features of subjects and correlation with IL-33 plasma level

The association between various characteristic features of patients and the healthy group and IL-33 plasma levels was assessed. As shown in Table 1, no factors were correlated with IL-33 level.

The alterations of IL-33 in various age ranges in MS patients and healthy subjects are shown in Figure 1. According to the Pearson correlation coefficient analysis, the relationship between mean IL-33 plasma level and increase in age was weak and direct in the MS group and was feeble and inverse in the control group (ρ(MS)=0.11 and ρ(Control)=0.13).

Figure 1: Plasma IL-33 levels based on age in the case and control groups.
Figure 1:

Plasma IL-33 levels based on age in the case and control groups.

Also, after separating the subjects based on gender, we observed a significant difference in female plasma IL-33 levels between both healthy and patient sub-groups (p=0.01), but not in the male subsets (Figure 2).

Figure 2: Plasma IL-33 levels in each of the case and control groups based on gender.
Figure 2:

Plasma IL-33 levels in each of the case and control groups based on gender.

Increased plasma levels of IL-33 in RRMS patients

The plasma levels of IL-33 were assessed in RRMS patients and in the control group. From Table 2 and Figure 3, the mean plasma levels of IL-33 in the RRMS patients were significantly higher than in the healthy subjects (p<0.05). We also classified case groups into the two subgroups treated and untreated patients, and after final assessment, the results revealed a significant difference in IL-33 levels between the control group and both subgroups of MS patients. Besides, the mean levels of IL-33 in treated patients were significantly lower than those in the new diagnosed cases (p>0.001).

Figure 3: Comparison of IL-33 plasma levels in RRMS patients and healthy subjects.
Figure 3:

Comparison of IL-33 plasma levels in RRMS patients and healthy subjects.

Discussion

Cytokines have a crucial role in the immunopathogenesis of MS. Many studies have demonstrated increased infiltrating leukocytes in the brain, which consequently lead to CNS lesions through inflammatory cytokines and activated transcription factors like NF-κB (36), (37), signal transducer and activation of transcription 1 (STAT1) (37), (38), (39) and STAT6 (40), (41). The provocative cytokines result in the over-expression of inflammation-mediated genes and accordingly release toxic molecules, which increase demyelination (42), (43), (44). Activation of NF-κB and Toll-like receptor signaling pathways stimulates TNF-α or IL-1β, which mediates IL-33 transcription (21), (27), (45), (46).

In the current study, we compared the plasma levels of IL-33 in RRMS patientswith those in the healthy subjects. We did not find any significant association among various factors of MS patients and healthy control groups and mean IL-33 plasma levels. To the best of our knowledge, this is the first study describing the relationship between IL-33 and various features of investigated subjects.

Many findings have proved the involvement of immunity and imbalance between pro- and anti-inflammatory cytokines in the pathogenesis of MS (19), (47), (48). IL-33 has a contradictory function in immunity. It is well known that IL-33 induces mRNA expression of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and IL-1β in the microglia. Binding of IL-33 to its receptor (ST2) induces activation of NF-κB and plays a critical role in the development of experimental autoimmune encephalomyelitis (EAE) (49), (50), (51). On the other hand, ST2 deficiency in dendritic cell surfaces leads to exacerbation of EAE (52). Furthermore, in response to IL-33, dendritic cells inhibit EAE (53). Interestingly, ST2 deficiency in BALB/C mice abrogates resistance to EAE (52). These are conflicting examples about the role of IL-33 in the immune system. Although clinical studies have shown that administration of IL-33 causes development of inflammation in the EAE model (54), other investigations have declared that IL-33 is not a necessary element for EAE pathogenesis (55). This is another evidence for the dual role of IL-33.

Previous studies have mentioned that IFN-β treatment could significantly suppress IL-33 plasma levels (56). In accordance with them, our assessments revealed that plasma levels of IL-33 in IFN-β-treated patients were significantly lower than in untreated patients (p<001). It could be noticed that IFN-β therapy in RRMS patients can modulate MS development, which would be a favorite future therapeutic target for MS patients (57), (58). Today, it has been admitted that IFN-β can be used as disease-modifying therapy agent that, due to its anti-inflammatory properties, can boost remyelination indirectly. While there are many new medications to treat MS patients, such as glatiramer acetate, or various corticosteroids, IFN-β is still one of the most commonly used drugs as a desirable and safe first-line treatment approach (59). Furthermore, follow-up studies have reported that using IFN-β can be beneficial for decreasing severity of disease (60).

It has been shown that IL-33 can biologically mediate several significant immune disorders, including rheumatoid arthritis, asthma, inflammatory bowel disease, dermatitis, cardiovascular disease and autoimmune hepatitis (18), (19). Moreover, the role of IL-33 in the immune system and the CNS is noticeable. In the immune system, the serum level of IL-33 that is elevated in response to the systemic inflammation results in the activation of various immune cells like dendritic cells, macrophages and lymphocytes. On the one hand, this initiation causes down-regulation of systemic inflammation. In the CNS, IL-33 stimulates vascular permeability in the blood-brain barrier (BBB) toward infiltrating immune cells, which consequently causes BBB disruption. Entry of immune cells into the CNS is responsible for beginning inflammation and promoting CNS resident immune cells like astrocytes to produce IL-33. It mediates infiltrating immune cells and/or CNS resident cells via binding to ST2 receptor, which causes cytokine and antibody generation and may modulate MS development. IL-33 also has a pivotal role in myelin damage/repair through its direct effect on oligodendrocytes (17) and glial activation, particularly astrocytes, and on induction of microglia proliferation, which causes the production of pro- and anti-inflammatory cytokines at the same time (61), (62).

Scientific attention has recently been directed toward the evaluation of IL-33 in the brain and immune-related diseases (63). There is enough evidence to show upregulated IL-33 expression by astrocytes and peripheral leukocytes in MS patients (64). Although it has been found that IL-33 induces pro-inflammatory type-2 responses, the anti-inflammatory properties of this cytokine have been thought to be beneficial in autoimmunity (65), (66) as well as in many other disorders (67).

In conclusion, in agreement with previous studies, our data confirmed that IL-33 levels were significantly higher in RRMS patients than in healthy controls, which suggested that IL-33 is a pro-inflammatory cytokine that might be involved in the pathogenesis of MS. Furthermore, IFN-β can modulate IL-33 production in RRMS patients and could be a new promising target for therapeutic strategies.

Highlights

  • IL-33 is an important cytokine playing a critical role in autoimmune diseases, especially MS.

  • Our assessment revealed a significant increase in IL-33 plasma levels of MS patients.

  • There was a reduction in IL-33 levels in IFN-β-treated patients compared with untreated patients.

  1. Conflict of interest statement: The authors declare no conflicts of interest.

References

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938–52.10.1056/NEJM200009283431307Search in Google Scholar PubMed

2. Kurtzke JF, Page WF, Murphy FM, Norman JE, Jr. Epidemiology of multiple sclerosis in US veterans. 4. Age at onset. Neuroepidemiology 1992; 11: 226–35.10.1159/000110935Search in Google Scholar PubMed

3. Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, Ebers GC, Canadian Collaborative Study Group. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5: 932–6.10.1016/S1474-4422(06)70581-6Search in Google Scholar PubMed

4. Ramagopalan SV, Yee IM, Dyment DA, Orton SM, Marrie RA, Sadovnick AD, Ebers GC, For the Canadian Collaborative Study Group. Parent-of-origin effect in multiple sclerosis: observations from interracial matings. Neurology 2009; 73: 602–5.10.1212/WNL.0b013e3181af33cfSearch in Google Scholar PubMed PubMed Central

5. Etemadifar M, Abtahi SH, Minagar A, Akbari M, Masaeli A, Tabrizi N. Late-onset multiple sclerosis in Isfahan, Iran. Arch Iran Med 2012; 15: 596–8.Search in Google Scholar

6. Lassmann H. Acute disseminated encephalomyelitis and multiple sclerosis. Brain 2010; 133(Pt 2): 317–9.10.1093/brain/awp342Search in Google Scholar PubMed

7. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurology 2001; 50: 121–7.10.1002/ana.1032Search in Google Scholar PubMed

8. Frohman EM, Racke MK, Raine CS. Multiple sclerosis–the plaque and its pathogenesis. N Engl J Med 2006; 354: 942–55.10.1056/NEJMra052130Search in Google Scholar PubMed

9. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115–21.10.1016/S1471-4914(00)01909-2Search in Google Scholar PubMed

10. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707–17.10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-QSearch in Google Scholar

11. Wekerle H. Immune pathogenesis of multiple sclerosis. Neurol Sci 2005; 26(Suppl 1): S1–2.10.1007/s10072-005-0386-9Search in Google Scholar

12. Kornek B, Lassmann H. Neuropathology of multiple sclerosis-new concepts. Brain Res Bull 2003; 61: 321–6.10.1016/S0361-9230(03)00095-9Search in Google Scholar

13. Vorob’eva AA, Ivanova MV, Fominykh VV, Zakharova MN, Zigangirova NA, Guliaeva NV. [Biomarkers in multiple sclerosis (a review and experimental data)]. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova/Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiat 2013; 113(10 Pt 2): 23–31.Search in Google Scholar

14. Katsavos S, Anagnostouli M. Biomarkers in multiple sclerosis: an up-to-date overview. Mult Scler Int 2013; 2013: 340508.10.1155/2013/340508Search in Google Scholar PubMed PubMed Central

15. Fernandez O, Martin R, Rovira A, Llufriu S, Vidal-Jordana A, Fernandez-Sanchez VE, Alvarez-Cermeno JC, Izquierdo G, Arroyo-Gonzalez R, Rodriguez-Antiguedad A, Casanova-Estruch B, Montalban X. Biomarkers in multiple sclerosis: an update for 2014. Rev Neurol 2014; 58: 553–70.10.33588/rn.5812.2014247Search in Google Scholar

16. Fernandez O, Arroyo-Gonzalez R, Rodriguez-Antiguedad A, Garcia-Merino JA, Comabella M, Villar LM, Izquierdo G, Tintoré M, Oreja-Guevara C, Álvarez-Cermeño JC, Meca-Lallana JE, Prieto JM, Ramió-Torrentà L, Martínez-Yélamos S, Montalban X. [Biomarkers in multiple sclerosis]. Rev Neurol 2013; 56: 375–90.10.33588/rn.5607.2013111Search in Google Scholar

17. Pei C, Barbour M, Fairlie-Clarke KJ, Allan D, Mu R, Jiang HR. Emerging role of interleukin-33 in autoimmune diseases. Immunology 2014; 141: 9–17.10.1111/imm.12174Search in Google Scholar PubMed PubMed Central

18. Kurowska-Stolarska M, Hueber A, Stolarski B, McInnes IB. Interleukin-33: a novel mediator with a role in distinct disease pathologies. J Intern Med 2011; 269: 29–35.10.1111/j.1365-2796.2010.02316.xSearch in Google Scholar PubMed

19. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010; 10: 103–10.10.1038/nri2692Search in Google Scholar PubMed

20. Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, Alysandratos KD, Kalogeromitros D, Asadi S, Stavrianeas N, Peterson E, Leeman S, Conti P. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 2010; 107: 4448–53.10.1073/pnas.1000803107Search in Google Scholar PubMed PubMed Central

21. Funakoshi-Tago M, Tago K, Hayakawa M, Tominaga S, Ohshio T, Sonoda Y, Kasahara T. TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell Signal 2008; 20: 1679–86.10.1016/j.cellsig.2008.05.013Search in Google Scholar PubMed

22. Funakoshi-Tago M, Tago K, Sato Y, Tominaga S, Kasahara T. JAK2 is an important signal transducer in IL-33-induced NF-kappaB activation. Cell Signal 2011; 23: 363–70.10.1016/j.cellsig.2010.10.006Search in Google Scholar PubMed

23. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008; 7: 827–40.10.1038/nrd2660Search in Google Scholar PubMed PubMed Central

24. Aoki S, Hayakawa M, Ozaki H, Takezako N, Obata H, Ibaraki N, Tsuru T, Tominaga S, Yanagisawa K. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem 2010; 335: 75–81.10.1007/s11010-009-0244-9Search in Google Scholar PubMed

25. Espinassous Q, Garcia-de-Paco E, Garcia-Verdugo I, Synguelakis M, von Aulock S, Sallenave JM, McKenzie AN, Kanellopoulos J. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol 2009; 183: 1446–55.10.4049/jimmunol.0803067Search in Google Scholar PubMed

26. Guo L, Wei G, Zhu J, Liao W, Leonard WJ, Zhao K, Paul W. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci USA 2009; 106: 13463–8.10.1073/pnas.0906988106Search in Google Scholar PubMed PubMed Central

27. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479–90.10.1016/j.immuni.2005.09.015Search in Google Scholar PubMed

28. Turnquist HR, Thomson AW. IL-33 broadens its repertoire to affect DC. Eur J Immunol 2009; 39: 3292–5.10.1002/eji.200940026Search in Google Scholar PubMed

29. Etemadifar M, Abtahi SH. Multiple sclerosis in Isfahan, Iran: past, present and future. Int J Prev Med 2012; 3: 301–2.10.1155/2012/232139Search in Google Scholar

30. Etemadifar M, Abtahi SH, Akbari M, Murray RT, Ramagopalan SV, Fereidan-Esfahani M. Multiple sclerosis in Isfahan, Iran: an update. Mult Scler 2014; 20: 1145–7.10.1177/1352458513516531Search in Google Scholar PubMed

31. Etemadifar M, Maghzi AH. Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran. Multiple Sclerosis 2011; 17: 1022–7.10.1177/1352458511401460Search in Google Scholar PubMed

32. Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi SH, Akbari M, Fereidan-Esfahani M. Epidemiology of multiple sclerosis in Iran: a systematic review. Eur Neurol 2013; 70: 356–63.10.1159/000355140Search in Google Scholar PubMed

33. Etemadifar M, Izadi S, Nikseresht A, Sharifian M, Sahraian MA, Nasr Z. Estimated prevalence and incidence of multiple sclerosis in iran. Eur Neurol 2014; 72: 370–4.10.1159/000365846Search in Google Scholar PubMed

34. Shajarian M, Alsahebfosoul F, Etemadifar M, Sedaghat N, Shahbazi M, Firouzabadi FP, Dezashibi HM. IL-23 plasma level measurement in relapsing remitting multiple sclerosis (RRMS) patients compared to healthy subjects. Immunol Invest 2015; 44: 36–44.10.3109/08820139.2014.930477Search in Google Scholar PubMed

35. Naderi S, Hejazi Z, Shajarian M, Alsahebfosoul F, Etemadifar M, Sedaghat N. IL-27 plasma level in relapsing remitting multiple sclerosis subjects: the double-faced cytokine. J Immunoassay Immunochem 2016; 37: 659–70.10.1080/15321819.2016.1195746Search in Google Scholar PubMed

36. Eggert M, Goertsches R, Seeck U, Dilk S, Neeck G, Zettl UK. Changes in the activation level of NF-κB in lymphocytes of MS patients during glucocorticoid pulse therapy. J Neurol Sci 2008; 264: 145–50.10.1016/j.jns.2007.08.026Search in Google Scholar PubMed

37. Gobin SJ, Montagne L, Van Zutphen M, Van Der Valk P, Van Den Elsen PJ, De Groot CJ. Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions. Glia 2001; 36: 68–77.10.1002/glia.1096Search in Google Scholar PubMed

38. Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, Reder AT. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 2002; 129: 205–15.10.1016/S0165-5728(02)00182-0Search in Google Scholar

39. Frisullo G, Angelucci F, Caggiula M, Nociti V, Iorio R, Patanella AK, Sancricca C, Mirabella M, Tonali PA, Batocchi AP. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. J Neurosci Res 2006; 84: 1027–36.10.1002/jnr.20995Search in Google Scholar PubMed

40. Christophi GP, Hudson CA, Gruber RC, Christophi CP, Mihai C, Mejico LJ, Jubelt B, Massa PT. SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients. Lab Invest 2008; 88: 243–55.10.1038/labinvest.3700720Search in Google Scholar PubMed PubMed Central

41. Zeis T, Graumann U, Reynolds R, Schaeren-Wiemers N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 2008; 131(Pt 1): 288–303.10.1093/brain/awm291Search in Google Scholar PubMed

42. Rodriguez M. Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis. Brain Pathol 2007; 17: 219–29.10.1111/j.1750-3639.2007.00065.xSearch in Google Scholar PubMed PubMed Central

43. Scarisbrick IA, Blaber SI, Lucchinetti CF, Genain CP, Blaber M, Rodriguez M. Activity of a newly identified serine protease in CNS demyelination. Brain 2002; 125(Pt 6): 1283–96.10.1093/brain/awf142Search in Google Scholar PubMed

44. Scarisbrick IA, Linbo R, Vandell AG, Keegan M, Blaber SI, Blaber M, Sneve D, Lucchinetti CF, Rodriguez M, Diamandis EP. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem 2008; 389: 739–45.10.1515/BC.2008.085Search in Google Scholar PubMed PubMed Central

45. Nile CJ, Barksby E, Jitprasertwong P, Preshaw PM, Taylor JJ. Expression and regulation of interleukin-33 in human monocytes. Immunology 2010; 130: 172–80.10.1111/j.1365-2567.2009.03221.xSearch in Google Scholar PubMed PubMed Central

46. Zhang L, Lu R, Zhao G, Pflugfelder SC, Li DQ. TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. Int J Biochem Cell Biol 2011; 43: 1383–91.10.1016/j.biocel.2011.06.003Search in Google Scholar PubMed PubMed Central

47. Amor S, Puentes F, Baker D, Van Der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010; 129: 154–69.10.1111/j.1365-2567.2009.03225.xSearch in Google Scholar PubMed PubMed Central

48. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17: 210–8.10.1111/j.1750-3639.2007.00064.xSearch in Google Scholar PubMed PubMed Central

49. Smith DE. The biological paths of IL-1 family members IL-18 and IL-33. J Leukocyte Biol 2011; 89: 383–92.10.1189/jlb.0810470Search in Google Scholar PubMed

50. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011; 8: 22.10.1186/1476-9255-8-22Search in Google Scholar PubMed PubMed Central

51. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, Martin MU. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-κB-stimulated gene transcription. J Immunol 2011; 187: 1609–16.10.4049/jimmunol.1003080Search in Google Scholar PubMed

52. Milovanovic M, Volarevic V, Ljujic B, Radosavljevic G, Jovanovic I, Arsenijevic N, Lukic ML. Deletion of IL-33R (ST2) abrogates resistance to EAE in BALB/C mice by enhancing polarization of APC to inflammatory phenotype. PLoS One 2012; 7: e45225.10.1371/journal.pone.0045225Search in Google Scholar PubMed PubMed Central

53. Le H, Kim W, Kim J, Cho HR, Kwon B. Interleukin-33: a mediator of inflammation targeting hematopoietic stem and progenitor cells and their progenies. Front Immunol 2013; 4: 104.10.3389/fimmu.2013.00104Search in Google Scholar PubMed PubMed Central

54. Jiang HR, Milovanovic M, Allan D, Niedbala W, Besnard AG, Fukada SY, Alves-Filho JC, Togbe D, Goodyear CS, Linington C, Xu D, Lukic ML, Liew FY. IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Euro J Immunol 2012; 42: 1804–14.10.1002/eji.201141947Search in Google Scholar PubMed

55. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, Nambu A, Abe T, Kiyonari H, Matsumoto K, Sudo K, Okumura K, Saito H, Nakae S. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Nat Acad Sci USA 2010; 107: 18581–6.10.1073/pnas.1003059107Search in Google Scholar PubMed PubMed Central

56. Christophi GP, Gruber RC, Panos M, Christophi RL, Jubelt B, Massa PT. Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin Immunol 2012; 142: 308–19.10.1016/j.clim.2011.11.007Search in Google Scholar PubMed PubMed Central

57. Kanda T. Interleukin-33/suppression of tumorigenicity 2 system: can it be a future therapeutic target for neuroimmunological disorders? Clin Exp Neuroimmunol 2013; 4: 255–6.10.1111/cen3.12081Search in Google Scholar

58. Wang S, Ding L, Liu S-S, Wang C, Leng R-X, Chen G-M, Fan YG, Pan HF, Ye DQ. IL-33: a potential therapeutic target in autoimmune diseases. J Investig Med 2012; 60: 1151–6.10.2310/JIM.0b013e31826d8fcbSearch in Google Scholar PubMed

59. Georgiou AM. Therapeutic strategies for multiple sclerosis: current data. Int J Health Allied Sci 2015; 4: 3.10.4103/2278-344X.149199Search in Google Scholar

60. Syrmos C, Orologas A. Efficacy of interferon in multiple sclerosis. PJNS 2013; 8: 15–8.Search in Google Scholar

61. Yasuoka S, Kawanokuchi J, Parajuli B, Jin S, Doi Y, Noda M, Sonobe Y, Takeuchi H, Mizuno T, Suzumura A. Production and functions of IL-33 in the central nervous system. Brain Res 2011; 1385: 8–17.10.1016/j.brainres.2011.02.045Search in Google Scholar PubMed

62. Hudson CA, Christophi GP, Gruber RC, Wilmore JR, Lawrence DA, Massa PT. Induction of IL-33 expression and activity in central nervous system glia. J Leukocyte Biol 2008; 84: 631–43.10.1189/jlb.1207830Search in Google Scholar PubMed PubMed Central

63. Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P. Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Experim Therap 2015; 354: 24–31.10.1124/jpet.114.222505Search in Google Scholar PubMed

64. Zhang F, Tossberg JT, Spurlock CF, Yao SY, Aune TM, Sriram S. Expression of IL-33 and its epigenetic regulation in multiple sclerosis. Ann Clin Transl Neurol 2014; 1: 307–18.10.1002/acn3.47Search in Google Scholar PubMed PubMed Central

65. Hardman C, Ogg G. Interleukin-33, friend and foe in type-2 immune responses. Curr Opin Immunol 2016; 42: 16–24.10.1016/j.coi.2016.05.004Search in Google Scholar PubMed

66. Zhao Q, Chen G. Role of IL-33 and its receptor in T cell-mediated autoimmune diseases. Biomed Res Int 2014; 2014: 1–10.10.1155/2014/587376Search in Google Scholar PubMed PubMed Central

67. Arshad MI, Khan HA, Noel G, Piquet-Pellorce C, Samson M. Potential therapeutic aspects of alarmin cytokine interleukin 33 or its inhibitors in various diseases. Clin Therap. 2016; 38: 1000–16. e1.10.1016/j.clinthera.2016.02.021Search in Google Scholar PubMed

Received: 2016-11-04
Accepted: 2016-11-25
Published Online: 2017-01-20

© 2017 Fereshteh Alsahebfosoul et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Downloaded on 29.3.2024 from https://www.degruyter.com/document/doi/10.1515/bmc-2016-0026/html
Scroll to top button